Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Finerenone is a selective non-steroidal mineralocorticoid receptor antagonist which reduces urinary albumin, and is beneficial in improving kidney outcomes in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD). Use of finerenone treatment in patients administered contemporary medications for T2D and CKD is still increasing. However, data on the effect of finerenone on urinary albumin when administered along with background medications such as renin-angiotensin system inhibitors (RASi: angiotensin-converting enzyme inhibitors or angiotensin receptor blockers), sodium-glucose cotransporter-2 inhibitors (SGLT2i), and glucagon-like peptide-1 receptor agonists (GLP-1RA) are limited.
This was a post hoc secondary analysis of an investigator-initiated, multicenter, prospective, placebo-controlled, double-blind, randomized clinical trial (FIVE-STAR) conducted in Japan to investigate the effects of 24-week of finerenone therapy on cardiovascular and kidney-related biomarkers (ClinicalTrials.gov NCT05887817). The trial included patients with T2D and CKD (estimated glomerular filtration rate [eGFR] of 25 to <90 mL/min/1.73 m2 and urinary albumin-to-creatinine ratio [UACR] of 30 to <3500 mg/g Cr). Participants were randomly allocated to receive either dose-adjusted finerenone or matching placebo. Participants with a baseline level of eGFR <60 mL/min/1.73 m2 were administered 10 mg of study drug, and an up-titration to 20 mg was encouraged after 4 weeks; whereas participants with a baseline eGFR ≥60 mL/min/1.73 m2 were administered an initial and maintenance dose of 20 mg of study drug. In the present study, changes in UACR from baseline to weeks 12 and 24 were analyzed using a mixed-effects model according to the baseline status of the medications of interest (RASi, SGLT2i, and GLP-1RA).
In the FIVE-STAR trial, a total of 102 patients were equally randomized, and 97 patients (median age 73 years, 68% men, median eGFR 56.2 mL/min/1.73 m2, and median UACR 193.8 mg/g Cr at randomization), who had UACR follow-up data, were included in this analysis. The user-rate of medications of interest at baseline was 79.4% for RASi, 62.9% for SGLT2i, 30.9% for GLP1RA, 35.1% for none or single-use among them, 49.5% for dual-combination (37.1% for ‘RASi and SGLT2i’, 4.1% for ‘RASi and GLP1-RA’, and 8.2% for ‘SGLT2i and GLP-1RA’), and 15.5% for triple-combination, respectively. Overall, the group ratio (finerenone vs. placebo) of proportional changes over 24 weeks in geometric mean of UACR was 0.71 (95% confidence interval, 0.51 to 0.99). The treatment effect of finerenone on urinary albumin was statistically consistent when administered along with the other medications, even with dual and triple usage (Figure).
The effect of finerenone on urinary albumin levels was consistent regardless of the background status of medications, such as RASi, SGLT2i, and GLP-1RA, in Japanese patients with T2D and CKD. Further studies are warranted to explore optimal treatment regimens to maximize the clinical benefits of finerenone in this patient population.
